Back HIV/AIDS HIV/AIDS Topics HIV Prevention

IAS 2015: U.S. PrEP Demo Project Finds People at Highest HIV Risk Take PrEP Most Consistently

An open-label demonstration project of Truvada pre-exposure prophylaxis (PrEP) in the U.S. has found generally high retention and adherence rates, with the highest adherence among people at the highest risk of HIV infection, researchers reported at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) last week in Vancouver. However, some groups appeared to have more difficulty taking PrEP -- most notably young people and black people, and it proved difficult to recruit black men and transgender women -- to the project.

alt

Read more:

IAS 2015: Intermittent PrEP May Be Robust Strategy for Anal Sex -- Vaginal Protection Less Certain

The pharmacodynamics (drug absorption and elimination rates) of the 2 drugs that comprise Truvada may favor the efficacy of intermittent pre-exposure prophylaxis (PrEP) more than previously thought, at least when it comes to protection from transmission via anal sex, according to a presentation at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention this week in Vancouver.

alt

Read more:

IAS 2015: No HIV Infections from Partners with Fully Suppressed Virus in Landmark Trial

Final follow up of the HPTN 052 study of treatment as prevention shows no evidence of HIV transmission from people with fully suppressed viral load to their partners, 4 years after the first results from thestudy demonstrated that early HIV treatment reduced the risk of HIV transmission by 96%, according to a report by Professor Myron Cohen at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention this week in Vancouver.

alt

Read more:

IAS 2015: HIV Treatment as Prevention Works [VIDEO]

The dramatic decreases in HIV sexual transmission among heterosexual couples when the positive partner is on suppressive antiretroviral therapy seen in the landmark HPTN 052 trial were sustained over the course of the multi-year study, according to final trial data presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention this week in Vancouver.

alt

Read more:

IAS 2015: Opioid Substitution Therapy Combined with HIV Treatment Saves More Lives

Providing opioid substitution therapy (OST) along with antiretroviral therapy (ART) to people who inject drugs results in a significantly greater reduction in deaths compared to providing either intervention alone, according to a study by Bohdan Nosyk and colleagues from the University of British Columbia Centre of Excellence in HIV/AIDS at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention this week in Vancouver. Research from Ukraine, also presented at the conference, showed that people receiving opioid substitution therapy had better engagement with HIV care.

alt

Read more: